

# Marie-Christine Kyrtsonis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2301358/publications.pdf>

Version: 2024-02-01

64  
papers

1,062  
citations

471061

17  
h-index

433756

31  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	0.6	5
2	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
3	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD". <i>Cancers</i> , 2022, 14, 2768.	1.7	6
4	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
5	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
6	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.	1.7	9
7	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	1.0	2
8	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
9	A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 4678-4678.	0.6	0
10	Validation of the simplified International Prognostic Score <sup>3</sup> in a Hellenic cohort of patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	1.2	4
11	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	2.0	9
12	Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. <i>Oral Diseases</i> , 2020, 26, 955-966.	1.5	43
13	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	0.6	7
14	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	0.6	0
15	Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
16	Continuous Clinical Remission with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
17	Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. <i>Leukemia and Lymphoma</i> , 2019, 60, 2939-2945.	0.6	16
18	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. <i>Anticancer Research</i> , 2019, 39, 2591-2598.	0.5	2

#	ARTICLE	IF	CITATIONS
19	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	1.3	6
20	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
21	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	2.8	35
22	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
23	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	1.3	3
24	High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine. <i>Leukemia and Lymphoma</i> , 2018, 59, 1264-1267.	0.6	0
25	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 100, 131-139.	1.1	1
26	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018, 97, 1671-1682.	0.8	17
27	Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis. <i>Anticancer Research</i> , 2018, 38, 4187-4191.	0.5	12
28	Evaluation of the performance of tuberculin skin test and Quantiferon-TB gold in tube test in patients with hematologic malignancies. <i>Infectious Diseases</i> , 2017, 49, 545-548.	1.4	1
29	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	0.6	62
30	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	1.1	37
31	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	0.6	9
32	Cadherin-11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma. <i>British Journal of Haematology</i> , 2017, 177, 813-816.	1.2	1
33	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
34	Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2016, 5, 2240-2248.	1.3	8
35	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	1.9	24
36	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	1.7	44

#	ARTICLE	IF	CITATIONS
37	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström's macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	0.6	108
38	New Insights into Malignant B-Cell Disorders. <i>BioMed Research International</i> , 2015, 2015, 1-3.	0.9	0
39	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3230-3232.	0.6	1
40	Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with Waldenström's Macroglobulinemia: Correlation with MYD88L265P Somatic Mutation Status, Clinical Features, and Outcome. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	14
41	and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	17
42	Serum Soluble TACI, a BlyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	11
43	New Insights into Monoclonal B-Cell Lymphocytosis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	17
44	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 571-582.	0.6	7
45	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP chemotherapy with or without Rituximab. <i>Hematological Oncology</i> , 2013, 31, 10-17.	0.8	30
46	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	0.8	55
47	Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia. <i>Advances in Hematology</i> , 2013, 2013, 1-7.	0.6	7
48	Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients' Course. <i>Blood</i> , 2013, 122, 3173-3173.	0.6	0
49	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
50	CD138 Expression Helps Distinguishing Waldenström's Macroglobulinemia (WM) From Splenic Marginal Zone Lymphoma (SMZL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 99-102.	0.2	19
51	Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. <i>The Application of Clinical Genetics</i> , 2010, 3, 41.	1.4	3
52	Staging Systems and Prognostic Factors as a Guide to Therapeutic Decisions in Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 110-117.	1.8	41
53	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. <i>Blood</i> , 2009, 114, 2886-2886.	0.6	0
54	Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. <i>Anticancer Research</i> , 2009, 29, 1811-6.	0.5	11

#	ARTICLE	IF	CITATIONS
55	Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. British Journal of Haematology, 2007, 137, 240-243.	1.2	108
56	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. Blood, 2006, 108, 2745-2745.	0.6	4
57	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. Blood, 2006, 108, 3522-3522.	0.6	0
58	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.. Blood, 2006, 108, 4655-4655.	0.6	0
59	Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN- $\alpha$ ). The Importance of Maintenance.. Blood, 2006, 108, 4718-4718.	0.6	0
60	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.. Blood, 2005, 106, 4785-4785.	0.6	0
61	Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.. Blood, 2005, 106, 5193-5193.	0.6	0
62	B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstrom's Macroglobulinemia (MW): A Comparative Fish Analysis.. Blood, 2004, 104, 4801-4801.	0.6	0
63	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Seminars in Oncology, 2003, 30, 201-205.	0.8	18
64	The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica, 2002, 87, 701-8; discussion 708.	1.7	34